Medicinal cannabis extracts are neuroprotective against Aβ
amyloid β
cannabis
lipid peroxidation
neuroprotection
phytocannabinoids
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
07 Sep 2024
07 Sep 2024
Historique:
revised:
16
08
2024
received:
14
02
2024
accepted:
23
08
2024
medline:
7
9
2024
pubmed:
7
9
2024
entrez:
7
9
2024
Statut:
aheadofprint
Résumé
Phytocannabinoids inhibit the aggregation and neurotoxicity of the neurotoxic Alzheimer's disease protein β amyloid (Aβ). We characterised the capacity of five proprietary medical cannabis extracts, heated and non-heated, with varying ratios of cannabidiol and Δ Neuroprotection against lipid peroxidation and Aβ Tetrahydrocannabinol (THC)/tetrahydrocannabinolic acid (THCA)-predominant cannabis extracts demonstrated the most significant overall neuroprotection against Aβ These findings highlight the variable neuroprotective activity of cannabis extracts containing major phytocannabinoids THC/THCA and cannabidiol (CBD)/cannabidiolic acid (CBDA) on Aβ-evoked neurotoxicity and inhibition of amyloid β aggregation. This may inform the future use of medicinal cannabis formulations in the treatment of Alzheimer's disease and dementia.
Sections du résumé
BACKGROUND
BACKGROUND
Phytocannabinoids inhibit the aggregation and neurotoxicity of the neurotoxic Alzheimer's disease protein β amyloid (Aβ). We characterised the capacity of five proprietary medical cannabis extracts, heated and non-heated, with varying ratios of cannabidiol and Δ
METHODS
METHODS
Neuroprotection against lipid peroxidation and Aβ
RESULTS
RESULTS
Tetrahydrocannabinol (THC)/tetrahydrocannabinolic acid (THCA)-predominant cannabis extracts demonstrated the most significant overall neuroprotection against Aβ
CONCLUSIONS
CONCLUSIONS
These findings highlight the variable neuroprotective activity of cannabis extracts containing major phytocannabinoids THC/THCA and cannabidiol (CBD)/cannabidiolic acid (CBDA) on Aβ-evoked neurotoxicity and inhibition of amyloid β aggregation. This may inform the future use of medicinal cannabis formulations in the treatment of Alzheimer's disease and dementia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Faculty of Health and Medical Sciences, University of Adelaide
Informations de copyright
© 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Références
Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry. 2006;28(2):153‐157. doi:10.1590/S1516‐44462006000200015
Cassano T, Villani R, Pace L, et al. From Cannabis sativa to cannabidiol: promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11:124. doi:10.3389/fphar.2020.00124
Ahmed W, Katz S. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12(11):668‐679.
Brenneisen R. Chemistry and analysis of phytocannabinoids and other cannabis constituents. In: ElSohly MA, ed. Marijuana and the cannabinoids. Humana Press; 2007:17‐49. doi:10.1007/978‐1‐59259‐947‐9_2
Hanuš LO, Meyer SM, Muñoz E, Taglialatela‐Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357‐1392. doi:10.1039/C6NP00074F
Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. In: Kinghorn AD, Falk H, Gibbons S, Ji K, eds. Phytocannabinoids: unraveling the complex chemistry and pharmacology of Cannabis sativa. Springer International Publishing; 2017:103‐131. doi:10.1007/978‐3‐319‐45541‐9_4
Berman P, Futoran K, Lewitus GM, et al. A new ESI‐LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis. Sci Rep. 2018;8(1):14280. doi:10.1038/s41598‐018‐32651‐4
Pollastro F, Caprioglio D, Del Prete D, et al. Cannabichromene. Nat Prod Commun. 2018;13(9):1934578X1801300922. doi:10.1177/1934578X1801300922
Janefjord E, Mååg JLV, Harvey BS, Smid SD. Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial‐activated neurotoxicity in vitro. Cell Mol Neurobiol. 2014;34(1):31‐42. doi:10.1007/s10571‐013‐9984‐x
O'Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899‐1910. doi:10.1111/bph.13497
Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134‐141. doi:10.1111/j.1471‐4159.2003.02327.x
Aso E, Ferrer I. CB2 cannabinoid receptor as potential target against Alzheimer's disease. Front Neurosci. 2016;10:243. doi:10.3389/fnins.2016.00243
Vallée A, Lecarpentier Y, Guillevin R, Vallée J‐N. Effects of cannabidiol interactions with Wnt/β‐catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease. Acta Biochim Biophys Sin. 2017;49(10):853‐866. doi:10.1093/abbs/gmx073
Bonn‐Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R. Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. Int Rev Psychiatry. 2018;30(3):277‐284. doi:10.1080/09540261.2018.1474730
Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Front Plant Sci. 2019;9:1969.
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344‐1364. doi:10.1111/j.1476‐5381.2011.01238.x
Ferber SG, Namdar D, Hen‐Shoval D, et al. The “entourage effect”: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol. 2020;18(2):87‐96. doi:10.2174/1570159X17666190903103923
Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD‐rich cannabis extracts over purified CBD in treatment‐resistant epilepsy: observational data meta‐analysis. Front Neurol. 2018;9:9. doi:10.3389/fneur.2018.00759
LaVigne JE, Hecksel R, Keresztes A, Streicher JM. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Sci Rep. 2021;11(1):8232. doi:10.1038/s41598‐021‐87740‐8
Raja A, Ahmadi S, de Costa F, Li N, Kerman K. Attenuation of oxidative stress by cannabinoids and cannabis extracts in differentiated neuronal cells. Pharmaceuticals (Basel). 2020;13(11):328. doi:10.3390/ph13110328
Aso E, Sánchez‐Pla A, Vegas‐Lozano E, Maldonado R, Ferrer I. Cannabis‐based medicine reduces multiple pathological processes in AβPP/PS1 mice. J Alzheimers Dis. 2015;43(3):977‐991. doi:10.3233/JAD‐141014
Patti F, Messina S, Solaro C, et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016;87(9):944‐951. doi:10.1136/jnnp‐2015‐312591
Lewis MA, Russo EB, Smith KM. Pharmacological foundations of Cannabis chemovars. Planta Med. 2018;84(4):225‐233. doi:10.1055/s‐0043‐122240
Olejar KJ, Kinney CA. Evaluation of thermo‐chemical conversion temperatures of cannabinoid acids in hemp (Cannabis sativa L.) biomass by pressurized liquid extraction. J Cannabis Res. 2021;3(1):40. doi:10.1186/s42238‐021‐00098‐6
Eichler M, Spinedi L, Unfer‐Grauwiler S, et al. Heat exposure of cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012;78(07):686‐691. doi:10.1055/s‐0031‐1298334
Chen C, Wongso I, Putnam D, Khir R, Pan Z. Effect of hot air and infrared drying on the retention of cannabidiol and terpenes in industrial hemp (Cannabis sativa L.). Ind Crops Prod. 2021;172:114051. doi:10.1016/j.indcrop.2021.114051
Tveden‐Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2023;133(4):391‐396. doi:10.1111/bcpt.13944
Wang M, Wang Y‐H, Avula B, et al. Decarboxylation study of acidic cannabinoids: a novel approach using ultra‐high‐performance supercritical fluid chromatography/photodiode array‐mass spectrometry. Cannabis Cannabinoid Res. 2016;1(1):262‐271. doi:10.1089/can.2016.0020
Veress T, Szanto JI, Leisztner L. Determination of cannabinoid acids by high‐performance liquid chromatography of their neutral derivatives formed by thermal decarboxylation: I. Study of the decarboxylation process in open reactors. J Chromatogr A. 1990;520:339‐347. doi:10.1016/0021‐9673(90)85118‐F
Laws JS III, Shrestha S, Smid SD. Cannabis terpenes display variable protective and anti‐aggregatory actions against neurotoxic β amyloid in vitro: highlighting the protective bioactivity of α‐bisabolol in motorneuronal‐like NSC‐34 cells. Neurotoxicology. 2022;90:81‐87. doi:10.1016/j.neuro.2022.03.001
Marsh DT, Das S, Ridell J, Smid SD. Structure‐activity relationships for flavone interactions with amyloid β reveal a novel anti‐aggregatory and neuroprotective effect of 2′,3′,4′‐trihydroxyflavone (2‐D08). Bioorg Med Chem. 2017;25(14):3827‐3834. doi:10.1016/j.bmc.2017.05.041
Kohn W, Becke AD, Parr RG. Density functional theory of electronic structure. J Phys Chem. 1996;100(31):12974‐12980. doi:10.1021/jp960669l
Harvey BS, Ohlsson KS, Mååg JLV, Musgrave IF, Smid SD. Contrasting protective effects of cannabinoids against oxidative stress and amyloid‐β evoked neurotoxicity in vitro. Neurotoxicology. 2012;33(1):138‐146. doi:10.1016/j.neuro.2011.12.015
Marsh DT, Sugiyama A, Imai Y, Kato R, Smid SD. The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β‐evoked neurotoxicity and changes in cell morphology in PC12 cells. Basic Clin Pharmacol Toxicol. 2024;134(3):293‐309. doi:10.1111/bcpt.13943
Lewis MM, Yang Y, Wasilewski E, Clarke HA, Kotra LP. Chemical profiling of medical cannabis extracts. ACS Omega. 2017;2(9):6091‐6103. doi:10.1021/acsomega.7b00996
Kim J, Choi P, Park YT, Kim T, Ham J, Kim JC. The cannabinoids, CBDA and THCA, rescue memory deficits and reduce amyloid‐beta and tau pathology in an Alzheimer's disease‐like mouse model. Int J Mol Sci. 2023;24(7):6827. doi:10.3390/ijms24076827
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833. doi:10.3390/ijms19030833
Castillo‐Arellano J, Canseco‐Alba A, Cutler SJ, León F. The polypharmacological effects of cannabidiol. Molecules. 2023;28(7):3271. doi:10.3390/molecules28073271
Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212‐2 attenuates amyloid‐beta‐induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR‐γ pathway. Neuropharmacology. 2012;63(4):653‐666. doi:10.1016/j.neuropharm.2012.05.013
Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M. Activation of the CB2 receptor system reverses amyloid‐induced memory deficiency. Neurobiol Aging. 2013;34(3):791‐804. doi:10.1016/j.neurobiolaging.2012.06.011
Koppel J, Vingtdeux V, Marambaud P, et al. CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol Med. 2013;19(1):357‐364. doi:10.2119/molmed.2013.00140
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 2017;103:1‐36. doi:10.1007/978‐3‐319‐45541‐9_1
Maggini V, Calvi L, Pelagatti T, et al. An optimized terpene profile for a new medical cannabis oil. Pharmaceutics. 2022;14(2):14. doi:10.3390/pharmaceutics14020298
Kumar R, Kumar R, Sharma N, Khurana N. Ameliorative effect of myrcene in mouse model of Alzheimer's disease. Eur J Pharmacol. 2021;911:174529. doi:10.1016/j.ejphar.2021.174529
Ciftci O, Oztanir MN, Cetin A. Neuroprotective effects of β‐myrcene after global cerebral ischemia/reperfusion‐mediated oxidative and neuronal damage in a C57BL/J6 mouse. Neurochem Res. 2014;39(9):1717‐1723. doi:10.1007/s11064‐014‐1365‐4
Laws JS 3rd, Smid SD. Characterizing cannabis‐prevalent terpenes for neuroprotection reveal a role for α and β‐pinenes in mitigating amyloid β‐evoked neurotoxicity and aggregation in vitro. Neurotoxicology. 2024;100:16‐24. doi:10.1016/j.neuro.2023.12.004
Khan‐Mohammadi‐Khorrami M‐K, Asle‐Rousta M, Rahnema M, Amini R. Neuroprotective effect of alpha‐pinene is mediated by suppression of the TNF‐α/NF‐κB pathway in Alzheimer's disease rat model. J Biochem Mol Toxicol. 2022;n/a(5):e23006. doi:10.1002/jbt.23006
Shin M, Liu QF, Choi B, et al. Neuroprotective effects of limonene (+) against Aβ42‐induced neurotoxicity in a Drosophila model of Alzheimer's disease. Biol Pharmaceut Bull. 2020;43(3):409‐417. doi:10.1248/bpb.b19‐00495
Marsh DT, Smid SD. Cannabis phytochemicals: a review of phytocannabinoid chemistry and bioactivity as neuroprotective agents. Aust J Chem. 2021;74:388‐404.